Most Read Articles
Elaine Soliven, 4 days ago

Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.

3 days ago
Among individuals with abdominal obesity, drinking beverages with artificial sweeteners (ASBs) or no sugar (USBs) instead of sugar-sweetened beverages (SSBs) helps lose body weight, a study has found. However, USBs have a more favourable effect on sweet taste preference compared with ASBs.
Stephen Padilla, 5 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Jairia Dela Cruz, 4 days ago
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.

Subgroup findings boost elagolix benefit in uterine fibroid-induced menstrual bleeding

Audrey Abella
29 May 2020

The addition of the oral GnRH* antagonist elagolix to hormonal add-back therapy (E2/NETA**) reduces menstrual blood loss (MBL) in women with heavy menstrual bleeding (HMB) associated with uterine fibroids (UF) and comorbid adenomyosis, with the extension phase showing benefits beyond 6 months, according to data presented at ACOG 2020.

Data were pooled from two investigational phase III studies – Elaris UF-1 and UF-2 – evaluating premenopausal women aged 18–51 years (n=790) with HMB (>80 mL MBL/cycle) tied to UF and baseline adenomyosis diagnosed by ultrasound and/or MRI. Women were randomized to receive elagolix BID 300 mg alone or with add-back therapy (E2 1 mg/NETA 0.5 mg), or placebo for 6 months.

 

UF + adenomyosis

Of the 126 participants who had adenomyosis at baseline, the fraction of women achieving the primary endpoint was significantly greater in the elagolix + E2/NETA vs the placebo arm (76.8 percent vs 12.1 percent; p<0.001). [ACOG 2020, abstract 15B]

Responder rate was also more significant with elagolix + E2/NETA vs placebo for the secondary endpoints of amenorrhoea and suppression of bleeding (p<0.001).

“[These findings show that more women in this subset achieved] <80 mL MBL during the final month and ≥50 percent reduction in MBL from baseline to final month,” said the researchers. “These results … were consistent with the all-subject group … suggesting that elagolix is effective in reducing HMB in women with UF despite the presence of adenomyosis,” they added.

 

Various subgroups

Across all subgroups, statistically significant differences were observed in favour of elagolix + E2/NETA over placebo in terms of the primary endpoint (72.2 percent vs 9.3 percent; p<0.001), mean change in MBL (–172.5 mL vs –0.8 mL; p<0.001), and the fraction of women who achieved amenorrhea (50.4 percent vs 4.5 percent; p<0.001). [ACOG 2020, abstract 23B]

“[These findings show that] elagolix with add-back therapy was effective in reducing HMB associated with UF regardless of age, body mass index, ethnicity, race, fibroid location based on FIGO*** classification, uterine and primary fibroid volume, and pregnancy history,” said the researchers.

 

Extension results

In the extension study, Elaris UF-EXTEND, elagolix recipients in Elaris UF-1 and UF-2 who completed the initial treatment period (n=433) were instructed to continue their regimen for an additional 6 months (up to 12 months). [ACOG 2020, abstract OP04-5D]

A drop in baseline MBL (mean, 224.7 mL) was observed with elagolix + E2/NETA as early as the first month of the extension period (mean, –186.5 mL), which was sustained through the sixth month (mean, –221.4 mL).

At the end of the 6-month extension period, nearly three-quarters (74.8 percent) had suppression of bleeding (ie, no bleeding; spotting allowed). About 72 percent of women with a baseline haemoglobin level of ≤10.5g/dL had a haemoglobin increase of >2 g/dL.

Of those who received up to 12 months of elagolix + E2/NETA, 87.9 percent met the primary endpoint. “[This finding implies that] up to 12 months of elagolix + E2/NETA provided sustained MBL reduction in women with UF,” said the researchers.

These subgroup and extension results add data to the initial findings of Elaris UF-1 and UF-2, thus boosting the therapeutic potential of elagolix in this patient subgroup. [N Engl J Med 2020; 382:328-340]

 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elaine Soliven, 4 days ago

Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.

3 days ago
Among individuals with abdominal obesity, drinking beverages with artificial sweeteners (ASBs) or no sugar (USBs) instead of sugar-sweetened beverages (SSBs) helps lose body weight, a study has found. However, USBs have a more favourable effect on sweet taste preference compared with ASBs.
Stephen Padilla, 5 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Jairia Dela Cruz, 4 days ago
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.